Obinutuzumab in Chronic Lymphocytic Leukemia: Design, Development and Place in Therapy

Drug Design, Development and Therapy- New Zealand

doi 10.2147/dddt.s104869

Full Text

Abstract

Available in

Categories

Pharmaceutical Science

Date

January 1, 2017

Authors

Othman Al-Sawaf

Kirsten Fischer

Publisher

Informa UK Limited

Related search

Real World Outcomes of Obinutuzumab Monotherapy in Patients With Chronic Lymphocytic Leukemia

Hematological Oncology

Cancer Research

English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

English

Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3-Year Follow-Up

Hematological Oncology

Cancer Research

English

Update on Therapy of Chronic Lymphocytic Leukemia

Journal of Clinical Oncology

Cancer Research

English

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma and Exposure–Response in CLL

CPT: Pharmacometrics and Systems Pharmacology

Cardiovascular Medicine

English

Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

OncoTargets and Therapy

English

Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib

Hematological Oncology

Cancer Research

English

Chronic Lymphocytic Leukemia in Pregnancy

Cancer Research

English

Accelerating CAR Therapy in CLL: The Development and Challenges of CAR T Cell Therapy for Chronic Lymphocytic Leukemia

American Journal of Hematology

English